American researchers associated with the Institute of Myology Research Centre have compiled and re-analysed the data accumulated in the placebo arms of several clinical trials in inclusion myositis (IMM) :
- 11 therapeutic trials were selected,
- they involved 257 participants who had received only a placebo,
- the main endpoints were changes in muscle strength and, in three studies, changes in the IBM-FRS, the functional scale specific to IBM,
- on average, patients showed a clear deterioration in these parameters over the observation period, and this deterioration is collectively measurable.
This work will enable us to better calculate the size of the groups (treated vs. controls) in future trials targeting IBM.
